Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Brivanib Alaninate · MGD013, BMS-582664

Small molecule · Inhibitor of VEGFR2 (kinase insert domain receptor) (KDR) · developed by Bristol-Myers Squibb

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is Brivanib Alaninate?

Brivanib alaninate is the alaninate salt of brivanib, a small-molecule inhibitor that strongly binds and inhibits VEGFR2, a tyrosine kinase receptor expressed mainly on vascular endothelial cells. It is studied in advanced hepatocellular carcinoma, both alone and in combination with MGD013.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MGD013, BMS-582664, BMS-582664-02
Drug type
Small molecule
Targets
VEGFR2 (kinase insert domain receptor) (KDR)
Mechanism
Inhibitor of VEGFR2 (kinase insert domain receptor) (KDR)
Pathways
angiogenesis, tumor cell growth
Therapy area
Oncology
Developer
Bristol-Myers Squibb
In trials of
ZLAB
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
U2Y5OFN795

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04212221 Phase 1/2 Advanced Hepatocellular Carcinoma (HCC) Terminated ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Hepatocellular Carcinoma (HCC)

Other drugs acting on KDR

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.